Canada - English - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 25mg - ranitidine (ranitidine hydrochloride) 25mg - histamine h2-antagonists

Canada - English - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 75mg - ranitidine (ranitidine hydrochloride) 75mg - histamine h2-antagonists

Canada - English - Health Canada

pharmapar inc - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Canada - English - Health Canada

pharmapar inc - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

Canada - English - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Canada - English - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg;   - film coated tablet - 150 mg - active: ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 336mg equivalent to ranitidine 300 mg;   - film coated tablet - 300 mg - active: ranitidine hydrochloride 336mg equivalent to ranitidine 300 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 335 equivalent to ranitidine 300 mg - film coated tablet - 300 mg - active: ranitidine hydrochloride 335 equivalent to ranitidine 300 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - long lasting relief from acid indigestion, heartburn and symptoms resulting from excess stomach acid.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out